Posology adjustments of oral antineoplastic agents for special populations: patients with renal impairment, hepatic impairment and hematologic toxicities
- 28 May 2018
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 17 (6) , 553-572
Abstract
Background: Oral antineoplastic agents (OAA) have reached 30–50% of all antineoplastic treatments. Although they seem safer than parenteral therapy, many severe problems can occur if the dose is not adequately adjusted in special situations. Our objective is to create a comprehensive guide with dosage adjustment recommendations for OAA in cases of renal and hepatic impairment and hematologic toxicities. Research design and methods: We analyzed all OAA approved by EMA in July 2017. We assessed data related to dose adjusted from the FDA’s and EMA’s summary of product characteristics. Results: 53 OAA were analyzed. We identified 44 (83%) OAA requiring dosage adjustments in special situations: 20 (37.7%) in renal impairment, 37 (69.8%) in hepatic impairment, and 22 (41.5%) in patients with hematologic toxicity. The dose adjustment recommendations varied in 31 (58.5%) OAA between the FDA and EMA. Detailed recommendations for each OAA were collated into comprehensive tables. Conclusions: Most OAA have to be adjusted in special situations. Given the number of OAA available for different indications, this review can serve as an easy tool to help health professionals dose these complex treatments.Keywords
Funding Information
- not funded
This publication has 15 references indexed in Scilit:
- Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research StatementJournal of Clinical Oncology, 2017
- Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literaturePatient Preference and Adherence, 2016
- Comorbidity in older adults with cancerJournal of Geriatric Oncology, 2016
- Pharmacotherapy follow-up of key points in the safety of oral antineoplastic agentsEuropean Journal of Cancer Care, 2016
- Effect of Renal Impairment on the Pharmacokinetics and Safety of AxitinibTargeted Oncology, 2015
- Prescription errors in cancer chemotherapy:Omissions supersede potentially harmful errorsJournal of Pharmacology and Pharmacotherapeutics, 2015
- Non-intercepted dose errors in prescribing anti-neoplastic treatment: a prospective, comparative cohort study2015
- Drug Management of Prostate Cancer: Prevalence and Consequences of Renal InsufficiencyClinical Genitourinary Cancer, 2009
- Medication Errors Among Adults and Children With Cancer in the Outpatient SettingJournal of Clinical Oncology, 2009
- Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug managementCancer, 2007